Jay M Sosenko1, Jay S Skyler2, Craig A Beam3, David Boulware4, Jeffrey L Mahon5, Jeffrey P Krischer4, Carla J Greenbaum6, Lisa E Rafkin2, Della Matheson2, Kevan C Herold7, Jerry P Palmer8. 1. Division of Endocrinology, University of Miami, Miami, FL jsosenko@med.miami.edu. 2. Division of Endocrinology, University of Miami, Miami, FL. 3. Division of Epidemiology and Biostatistics, University of Western Michigan School of Medicine, Kalamazoo, MI. 4. Division of Informatics and Biostatistics, University of South Florida, Tampa, FL. 5. Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada. 6. Benaroya Research Institute at Virginia Mason, Seattle, WA. 7. Department of Immunobiology, Yale University School of Medicine, New Haven, CT. 8. VA Puget Sound Health Care System; Division of Endocrinology, Metabolism, and Nutrition, University of Washington, Seattle, WA.
Abstract
OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.
OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.
Authors: Jeffrey L Mahon; Jay M Sosenko; Lisa Rafkin-Mervis; Heidi Krause-Steinrauf; John M Lachin; Clinton Thompson; Polly J Bingley; Ezio Bonifacio; Jerry P Palmer; George S Eisenbarth; Joseph Wolfsdorf; Jay S Skyler Journal: Pediatr Diabetes Date: 2008-09-24 Impact factor: 4.866
Authors: Randie R Little; Curt L Rohlfing; Alethea L Tennill; Richard W Madsen; Kenneth S Polonsky; Gary L Myers; Carla J Greenbaum; Jerry P Palmer; Eduard Rogatsky; Daniel T Stein Journal: Clin Chem Date: 2008-04-17 Impact factor: 8.327
Authors: Jay M Sosenko; Jerry P Palmer; Carla J Greenbaum; Jeffrey Mahon; Catherine Cowie; Jeffrey P Krischer; H Peter Chase; Neil H White; Bruce Buckingham; Kevan C Herold; David Cuthbertson; Jay S Skyler Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Jay S Skyler; Jeffrey P Krischer; Joseph Wolfsdorf; Catherine Cowie; Jerry P Palmer; Carla Greenbaum; David Cuthbertson; Lisa E Rafkin-Mervis; H Peter Chase; Ellen Leschek Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112
Authors: Jay M Sosenko; Jay S Skyler; Jeffrey Mahon; Jeffrey P Krischer; Craig A Beam; David C Boulware; Carla J Greenbaum; Lisa E Rafkin; Catherine Cowie; David Cuthbertson; Jerry P Palmer Journal: Diabetes Care Date: 2011-06-16 Impact factor: 19.112
Authors: Jay M Sosenko; Jerry P Palmer; Lisa E Rafkin; Jeffrey P Krischer; David Cuthbertson; Carla J Greenbaum; George Eisenbarth; Jay S Skyler Journal: Diabetes Care Date: 2009-12-23 Impact factor: 17.152
Authors: Jay M Sosenko; Jerry P Palmer; Lisa Rafkin-Mervis; Jeffrey P Krischer; David Cuthbertson; Della Matheson; Jay S Skyler Journal: Diabetes Care Date: 2008-07-23 Impact factor: 17.152
Authors: Jay M Sosenko; Liping Yu; Jay S Skyler; Jeffrey P Krischer; Peter A Gottlieb; David Boulware; Dongmei Miao; Jerry P Palmer; Andrea K Steck Journal: Diabetes Technol Ther Date: 2017-02-08 Impact factor: 6.118
Authors: Alberto Pugliese; David Boulware; Liping Yu; Sunanda Babu; Andrea K Steck; Dorothy Becker; Henry Rodriguez; Linda DiMeglio; Carmella Evans-Molina; Leonard C Harrison; Desmond Schatz; Jerry P Palmer; Carla Greenbaum; George S Eisenbarth; Jay M Sosenko Journal: Diabetes Date: 2016-01-28 Impact factor: 9.461